• IM Cannabis published management discussion and analysis for Q1 2026, showing net revenue fell to CAD 8.68 million from CAD 12.5 million year earlier, driven mainly by weaker Germany sales tied to shipment delays, product mix shifts, pricing, volume, reduced imports.
• Germany revenue dropped to CAD 4.28 million from CAD 7.71 million; Israel revenue eased to CAD 4.4 million from CAD 4.8 million.
• Gross profit before fair value impacts slid to CAD 1.42 million from CAD 3.45 million; gross margin narrowed to 16% from 28%.
• Operating result swung to loss of CAD 1.68 million from profit of CAD 158,000; net result moved to loss of CAD 2.47 million from profit of CAD 175,000; financing expense rose to CAD 832,000 from CAD 12,000.
• Liquidity remained tight with cash and restricted cash of CAD 1.15 million, working capital deficit of CAD 12.6 million; management flagged uncertainty over ability to fund operations through rest of 2026 without additional capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IM Cannabis Corp. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.